Medtronic 2013 Annual Report Download - page 21

Download and view the complete annual report

Please find page 21 of the 2013 Medtronic annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 145

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145

75732me_10K.indd 6 6/25/13 6:39 PM
Table of Contents
treating heart failure patients who have one of several types of Medtronic CRT-Ds or ICDs. Patient Home Monitors transfer data
from pacemakers, ICDs, and CRT-Ds from patients' homes to a web-based system that their health care provider can view.
The charts below set forth net sales of our CRDM products as a percentage of our total net sales for each of the last three fiscal
years:
32%
68%
Fiscal Year 2011
(dollars in millions)
CRDM
$5,010
All Other
$10,498
31%
69%
Fiscal Year 2012
(dollars in millions)
All Other
$11,177
CRDM
$5,007
30%
70%
Fiscal Year 2013
(dollars in millions)
All Other
$11,668
CRDM
$4,922
Customers and Competitors
The primary medical specialists who use our CRDM products include electrophysiologists, implanting cardiologists, heart failure
specialists, and cardiovascular surgeons. Our primary competitors in the CRDM business are St. Jude Medical, Inc. (St. Jude),
Boston Scientific Corporation (Boston Scientific), Biotronik, Inc., and Sorin Group (Sorin).
Coronary
Coronary includes therapies to treat coronary artery disease (CAD) and hypertension. The products contained within this business
include coronary stents and related delivery systems, including a broad line of balloon angioplasty catheters, guide catheters,
guidewires, diagnostic catheters, and accessories.
The following are the principal products offered by our Coronary business:
Percutaneous Coronary Intervention (PCI). PCI encompasses a variety of procedures used to treat patients with CAD. CAD
is commonly treated with balloon angioplasty, which is performed to open narrowed heart vessels by inserting a balloon catheter
into the vessel and advancing it to the site of the blockage where it is inflated to widen the obstructed vessel. Balloon angioplasty
can be followed up with a coronary stent, a support device which works as scaffolding to keep the vessel open following the
intervention. Our PCI stent products include our Resolute Integrity, Resolute, and Endeavor drug-eluting stent systems as well as
our Integrity, Driver, and Micro-Driver bare metal stent systems.
Renal Denervation. The Symplicity Catheter System is designed to treat chronic uncontrolled hypertension by delivering radio
frequency energy through the renal artery walls to denervate the renal nerves, or ablate the nerves lining the renal arteries. This
technology has received CE Mark approval and is available in select markets. The Company is currently conducting a U.S. IDE
study (HTN-3) for U.S. approval and the HTN-Japan study for local approval as well.
The charts below set forth net sales of our Coronary products as a percentage of our total net sales for each of the last three
fiscal years:
9%
91%
Fiscal Year 2011
(dollars in millions)
Coronary
$1,466
All Other
$14,042
10%
90%
Fiscal Year 2012
(dollars in millions)
All Other
$14,586
Coronary
$1,598
11%
89%
Fiscal Year 2013
(dollars in millions)
All Other
$14,817
Coronary
$1,773
3